← All trials
NCT04931563
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 13, 2021
- Primary completion
- Jun 13, 2024
- Completion date
- Jun 13, 2024
- First posted
- Jun 18, 2021
- Last posted
- Nov 9, 2021
- Enrollment
- 328
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.